Breaking News, Collaborations & Alliances

QSAM Biosciences, RLS Join Forces for Clinical-Stage Bone Cancer Treatment

Partnership is latest in series of RLS efforts to expand CDMO business and clinical trial capability.

QSAM Biosciences Inc., a clinical stage biotechnology company developing next-generation therapeutic radiopharmaceuticals, and RLS (USA) Inc., the third-largest nuclear medicine pharmacy network in the U.S., entered into a commercial supply and clinical dose preparation agreement for the therapeutic radiopharmaceutical drug candidate CycloSam (Samarium-153 DOTMP), a promising clinical-stage treatment for metastatic and primary bone cancer in adults and children. QSAM is actively enrolling pat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters